{"id":"ado-trastuzumab-emtamsine","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"20-30%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Vomiting"},{"rate":"10-20%","effect":"Hair loss"},{"rate":"5-10%","effect":"Neutropenia"},{"rate":"5-10%","effect":"Thrombocytopenia"},{"rate":"5-10%","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL1201585","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by binding to the HER2 receptor on the surface of cancer cells, which then internalizes the conjugate and releases the cytotoxic agent, causing cell death. This targeted approach aims to minimize harm to healthy cells.","oneSentence":"Ado-trastuzumab emtansine is a HER2-targeting antibody-drug conjugate that delivers a cytotoxic agent to HER2-positive cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:19:47.757Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjuvant treatment of HER2-positive breast cancer"}]},"trialDetails":[{"nctId":"NCT04158258","phase":"","title":"A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-02-21","conditions":"Breast Cancer","enrollment":2907}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Kadcyla"],"phase":"phase_2","status":"active","brandName":"Ado-trastuzumab emtamsine","genericName":"Ado-trastuzumab emtamsine","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ado-trastuzumab emtansine is a HER2-targeting antibody-drug conjugate that delivers a cytotoxic agent to HER2-positive cancer cells. Used for Adjuvant treatment of HER2-positive breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}